Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Epilepsy 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 73Temozolomide 68Specimen Handling 48Radiotherapy 40Radiosurgery 29Bevacizumab 26Radiation 25Cyclophosphamide 25Nivolumab 21Biopsy 21pembrolizumab 20Carboplatin 16X-Rays 14Lomustine 13Ipilimumab 13fludarabine 12Irinotecan 12Vincristine 11Topotecan 11Surgical Procedures, Operative 11Cisplatin 11Blood Specimen Collection 11trametinib 9dinutuximab 9Immunoglobulin G 8Etoposide 8Doxorubicin 8lutetium Lu 177 dotatate 7fludarabine phosphate 7atezolizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
brivaracetam × CNS × 90 days × Clear all
NCT05029960 2026-06-03

Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

University of Rochester

Phase EARLY_PHASE1 Terminated
3 enrolled
CNS

Brain Neoplasms, Epilepsy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡